Study guide · Dimension of care
Chronic
30% target (ours) · 9 sections
The MCC describes chronic illness as illness of long duration, including but not limited to illness that progresses slowly. Questions follow a patient over months or years, usually in family practice, clinic, home care or long-term care. You must confirm the diagnosis correctly, set targets, choose first-line and add-on drugs, and screen for complications. Many questions test Canadian guideline steps for diabetes, hypertension, lipids, COPD, asthma and kidney disease. Others test older adults with many conditions and many drugs, chronic pain and opioids, dementia, palliative care and the law on medical assistance in dying.
A study feature written by ExamDragon, not part of the real exam. The domain and its definition are the MCC's; the teaching, examples and traps are ours, tied to the current Canadian guidelines listed at the end.
At a glance
Dimension of careof the exam, our working target (the MCC's weighting is not yet read)
- Target
- 30%
- Sections
- 9
- Key terms
- 8
What this guide covers, section by section
1Type 2 diabetes
- Diagnosis: fasting plasma glucose 7.0 mmol/L or more, A1C 6.5% or more, or a 2-hour glucose of 11.1 mmol/L or more on an oral glucose tolerance test. Without clear symptoms, repeat to confirm.
- The A1C target for most adults is 7.0% or less. Frail older adults and people with frequent hypoglycemia have a less strict target.
- Metformin is first-line for most people, with healthy eating and activity.
- With atherosclerotic heart disease, add a GLP-1 receptor agonist or an SGLT2 inhibitor with proven benefit. With heart failure or chronic kidney disease, add an SGLT2 inhibitor. Do this whatever the A1C.
- Screen for complications every year: urine albumin to creatinine ratio and eGFR, and a foot examination. Eye screening every 1 to 2 years.
- Most adults with diabetes aged 40 and over should take a statin. Many also need an ACE inhibitor or ARB.
- Sulfonylureas and insulin can cause hypoglycemia. Teach the patient to recognize and treat it.
- A worked exampleA 70-year-old man with diabetes and heart failure has an A1C of 7.4% on metformin. Adding an SGLT2 inhibitor improves heart failure outcomes, so it is the best choice even though his A1C is close to target.
- Where questions turnDo not choose a drug only by its effect on glucose. On the exam, heart and kidney benefit often decides the answer.
2Hypertension
- Confirm the diagnosis with readings outside the office: ambulatory monitoring is preferred, home readings are an option.
- Out-of-office threshold (Hypertension Canada, 2025): a daytime ambulatory or home average of 130/80 mm Hg or more confirms hypertension. An automated office reading of 130/80 or more is a reason to confirm outside the office.
- Very high readings, or signs of organ damage, need prompt assessment and treatment without waiting for out-of-office readings (standard practice).
- Start drugs at 140/90 or more, or at a systolic of 130 to 139 when cardiovascular risk is high.
- Target: a systolic pressure below 130 mm Hg for most adults on treatment, if tolerated (Hypertension Canada, 2025). Relax the target for frailty, low blood pressure on standing or side effects.
- Start most patients on two low-dose drugs, ideally in a single pill, from two of these classes: an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, a long-acting calcium channel blocker. Never combine an ACE inhibitor with an ARB.
- Look for secondary causes in young patients, resistant hypertension, low potassium or sudden onset.
- A worked exampleA 38-year-old woman has blood pressure 168/102 mm Hg and a potassium of 3.0 mmol/L (normal 3.5 to 5.0) without diuretics. This suggests primary aldosteronism, so the next step is an aldosterone to renin ratio.
- Where questions turnDo not diagnose hypertension from one office visit when the reading is only mildly high and there is no organ damage.
3Cardiovascular risk and lipids
- Screen lipids in men and women 40 and over, or earlier with risk factors such as diabetes, smoking or family history.
- Some conditions need a statin without a risk score: atherosclerotic disease, most adults with diabetes, chronic kidney disease, and LDL 5.0 mmol/L or more.
- For others, estimate 10-year risk with the Framingham risk score. High risk (20% or more) means a statin.
- Lifestyle comes with every plan: stop smoking, eat well, be active, keep a healthy weight.
- In established heart disease, intensify therapy if LDL stays 1.8 mmol/L or more on a maximum tolerated statin. Add ezetimibe first, then a PCSK9 inhibitor.
- Measure lipoprotein(a) once in a lifetime as part of the first lipid assessment.
- A worked exampleA 60-year-old man had a stroke last year. On high-dose atorvastatin his LDL is 2.3 mmol/L. He is above the threshold, so ezetimibe is added.
- Where questions turnDo not use a risk calculator for a patient who already has heart disease. They need a statin already.
4COPD and asthma
- COPD is confirmed by spirometry: after a bronchodilator, FEV1/FVC stays below 0.70.
- Stopping smoking is the single most useful step in COPD. Offer support at every visit.
- COPD drugs: start with a long-acting bronchodilator (LAMA or LABA). Move to LAMA plus LABA if symptoms remain. Add an inhaled corticosteroid mainly for frequent exacerbations with high eosinophils.
- COPD care also includes vaccines, pulmonary rehabilitation, an action plan and oxygen only if resting oxygen is low.
- Asthma shows variable airflow that improves with a bronchodilator. Spirometry with reversibility, or other tests, confirms it.
- Most people with asthma need an inhaled corticosteroid. Relying on a short-acting bronchodilator alone is unsafe. In mild asthma from age 12, as-needed budesonide-formoterol is an option.
- Check inhaler technique and adherence before adding a drug.
- A worked exampleA 30-year-old uses salbutamol 5 times a week and wakes at night with cough. Her asthma is not controlled. She needs an inhaled corticosteroid-containing treatment, after checking how she uses her inhaler.
- Where questions turnDo not step up treatment before checking technique, adherence and triggers. This is often the best first answer.
5Chronic kidney disease
- CKD means eGFR below 60 mL/min/1.73 m2, or kidney damage such as albuminuria, for more than 3 months.
- Stage CKD with both eGFR and urine albumin to creatinine ratio. Diabetes Canada uses an ACR of 2.0 mg/mmol or more as abnormal.
- Use an ACE inhibitor or ARB for albuminuria. Check creatinine and potassium 1 to 2 weeks after starting.
- SGLT2 inhibitors slow CKD in people with type 2 diabetes and in many without diabetes.
- Avoid nephrotoxic drugs, such as NSAIDs, and adjust doses of drugs cleared by the kidney.
- Refer to nephrology for an eGFR below 30, a very high ACR, a fast fall in eGFR, or unexplained blood in the urine.
- A worked exampleA 64-year-old with diabetes has an ACR of 15 mg/mmol and normal eGFR. Starting an ACE inhibitor and an SGLT2 inhibitor protects his kidneys.
- Where questions turnDo not stop an ACE inhibitor for a small rise in creatinine (under about 30%). A small rise is expected.
6Chronic pain and opioids
- For chronic non-cancer pain, optimize non-opioid drugs and non-drug treatment first, such as exercise, physical therapy and psychological therapy.
- The 2024 Canadian Opioid Prescribing Guideline, which replaced the 2017 guideline, recommends against an opioid trial after an opioid overdose or with active alcohol use disorder, and suggests against one with a history of any substance use disorder or with an active mental health disorder.
- If an opioid trial is chosen, agree on goals, keep the dose as low as possible and stop the trial if pain and function do not clearly improve within about 2 months.
- Offer a trial of tapering to everyone on long-term opioid therapy, and offer it again every 6 to 12 months if they decline.
- Taper slowly with support, and never force a taper. Abrupt stopping causes withdrawal, more pain and risk of unsafe drug use.
- Avoid combining opioids with benzodiazepines or other sedatives. Offer a naloxone kit to people on opioids.
- The 2024 guideline revised the 2017 dose thresholds, so questions test the principles both share: non-opioid treatment first, risk factors, monitoring, offering a taper and no forced tapering.
- A worked exampleA 49-year-old with knee osteoarthritis asks for oxycodone. The doctor offers exercise therapy, weight support, topical or oral NSAIDs if safe, and acetaminophen, and explains why opioids are not first-line.
- Where questions turnDo not choose 'stop all opioids today' for a stable patient on a high dose. A slow, supported taper is safer.
7Dementia
- Take a history from the patient and from someone who knows them well. Ask about function: money, medications, driving, cooking.
- Use a cognitive test such as the MoCA. Check for depression, delirium, hearing and vision loss.
- Look for reversible contributors: CBC, TSH, vitamin B12, electrolytes, calcium and glucose, and a review of drugs, especially anticholinergics and sedatives.
- Cholinesterase inhibitors help some people with mild to moderate Alzheimer disease. Memantine is used in moderate to severe disease.
- For agitation, try non-drug approaches first. Antipsychotics carry risks, including stroke and death, and are kept for severe distress or danger.
- Capacity is decision-specific. A person with dementia may still decide some things.
- Physicians have duties to report patients who may be unsafe to drive. The rules differ by province.
- A worked exampleAn 80-year-old woman with dementia now gets lost driving. The doctor discusses safety with her, reports to the provincial licensing authority as the province requires, and helps plan other transport.
- Where questions turnDo not assume a diagnosis of dementia removes all capacity. Assess each decision on its own.
8Multimorbidity, deprescribing and frailty
- Older adults often have several diseases and take many drugs. Each new symptom may be a drug side effect.
- Review all drugs at least yearly: purpose, benefit, harm, and the patient's goals.
- Tools such as the Beers criteria and STOPP list risky drugs in older adults. Deprescribing algorithms exist for benzodiazepines, proton pump inhibitors, antipsychotics and sulfonylureas.
- Taper drugs one at a time and watch for withdrawal or return of symptoms.
- Falls: review drugs, check vision, feet, postural blood pressure and gait, and refer for exercise and home safety.
- Match care to goals. In frailty, a less strict A1C or blood pressure target is often safer.
- A worked exampleAn 87-year-old in long-term care falls twice. She takes zopiclone, oxybutynin and three blood pressure drugs, and her standing blood pressure drops. The team tapers zopiclone, stops oxybutynin and reduces a blood pressure drug.
- Where questions turnDo not add a new drug to treat the side effect of another drug. Look for the cause in the medication list.
9Palliative care and medical assistance in dying
- A palliative approach can start early in any serious illness, alongside treatment aimed at control or cure.
- Hold goals of care conversations: what the patient understands, hopes, fears, and what matters most.
- Opioids treat pain and breathlessness at the end of life. Used properly, they do not hasten death.
- When a patient cannot decide, the substitute decision-maker follows the patient's known wishes, or their best interests if wishes are unknown.
- Medical assistance in dying (MAID) is legal under the Criminal Code since 2016. The patient must be 18 or older, eligible for publicly funded care, have a grievous and irremediable condition, make a voluntary request, and give informed consent.
- Since 2021 there are two tracks: natural death reasonably foreseeable, or not. The second track has extra safeguards, including a minimum 90-day assessment.
- Mental illness as the only condition is excluded for now; Parliament has delayed that change. A physician who objects must still follow their college's rules on referral or transfer of care.
- A worked exampleA 68-year-old with metastatic lung cancer has distressing breathlessness at rest. The team gives low-dose morphine, a fan, and positioning, and discusses goals of care with the patient and family.
- Where questions turnDo not withhold opioids at the end of life out of fear of hastening death. Proper dosing relieves suffering safely.
Key terms
- A1C
- A blood test that shows average glucose over about 3 months.
- SGLT2 inhibitor
- A diabetes drug that makes the kidneys pass glucose into the urine. It also protects the heart and kidneys.
- Ambulatory monitoring
- A device that measures blood pressure many times over 24 hours.
- LDL
- Low-density lipoprotein cholesterol, the main target of lipid treatment.
- Albumin to creatinine ratio
- A urine test that measures albumin and shows early kidney damage.
- Morphine equivalent
- An opioid dose converted to the matching dose of oral morphine, to compare drugs.
- Deprescribing
- Planned reduction or stopping of drugs that may cause more harm than good.
- MAID
- Medical assistance in dying, legal in Canada under the Criminal Code with strict criteria.
The guidelines this guide rests on
- Diabetes Canada Clinical Practice Guidelines, 2018, with the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2024 Update and the Chronic Kidney Disease in Diabetes: 2025 Update
- Hypertension Canada, Guideline for the diagnosis and treatment of hypertension in adults in primary care, CMAJ, 2025
- Canadian Cardiovascular Society, Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults, 2021
- Canadian Thoracic Society, 2023 guideline update on pharmacotherapy in patients with COPD
- Canadian Thoracic Society, Guideline on asthma management, 2021 update
- Michael G. DeGroote National Pain Centre, McMaster University, 2024 Canadian Opioid Prescribing Guideline (Health Canada funded revision of the 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain), 2024
- Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, fifth conference, 2020
- Criminal Code of Canada, medical assistance in dying provisions, as amended in 2021
Built to the MCC's blueprint for the MCCQE. The explanations, worked examples and traps are ExamDragon's own. Every source this path is built on. MCCQE is a mark of the Medical Council of Canada, which does not endorse or review this product.
